Cart
sales@molnova.com
Palazestrant
CAS No. 2092925-89-6
Palazestrant( —— )
Catalog No. M36480 CAS No. 2092925-89-6
Palazestrant (OP-1250) is an orally available and highly potent estrogen receptor antagonist and selective ER degrader with antitumor activity.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 445 | Get Quote |
|
| 5MG | 686 | Get Quote |
|
| 10MG | 938 | Get Quote |
|
| 25MG | 1398 | Get Quote |
|
| 50MG | 1822 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NamePalazestrant
-
NoteResearch use only, not for human use.
-
Brief DescriptionPalazestrant (OP-1250) is an orally available and highly potent estrogen receptor antagonist and selective ER degrader with antitumor activity.
-
DescriptionPalazestrant is an antiestrogen and antineoplastic agent. Palazestrant in combination with a HER2 inhibitor, works on ER+/HER2+ cancer.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayEndocrinology/Hormones
-
TargetEstrogen Receptor/ERR
-
RecptorEstrogen/progestogen Receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2092925-89-6
-
Formula Weight449.6
-
Molecular FormulaC28H36FN3O
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC(C(C)(C)F)N1[C@@H](C2=C(C=3C(N2)=CC=CC3)C[C@H]1C)C4=CC=C(OC5CN(CCC)C5)C=C4
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Harmon CL, et al. Methods of treating estrogen receptor-associated diseases such as ER+/HER2+ cancer using an estrogen receptor antagonist: World Intellectual Property Organization, WO2023283329. 2023-01-12.
molnova catalog
related products
-
α-Zearalenol
α-Zearalenol is one of the major metabolites of Zearalenone. α-Zearalenol has structural analogy to estrogen, thus α-Zearalenol can bind to estrogen receptors (ERs).
-
PROTAC ERRα ligand 1
PROTAC ERRα ligand 1 is an α (ERRα) antagonist of estrogen-related receptor (IC50s of 0.04 and 2.8 μM for ERRα and ERRγ, respectively).
-
Medicarpin (b)
(+)-Medicarpin potently inhibits osteoclastogenesis and promotes bone healing and increases bone mass by osteoblast differentiation with estrogen receptor (ER) β-mediated osteogenic action.
